Sugi Predict

Sugi Predict / Compounds / SCHEMBL1246063

SCHEMBL1246063

SCHEMBL1246063

CCOC(=O)CCc1ccccc1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 3/20 0.76
▸ CYP4A11 Q02928 3/20 0.76
▸ ALDH1A1 P00352 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ CA12 O43570 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ CA7 P43166 1/20 0.49
▸ CA9 Q16790 1/20 0.49
▸ CA14 Q9ULX7 1/20 0.49
▸ MAPT P10636 1/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8969442 0.94 CYP4F2 (0.68) CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2
SCHEMBL11410892 0.94 CYP4F2 (0.68) CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2
SCHEMBL7722448 0.90 CYP4F2 (0.70) CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2
SCHEMBL69660 0.89 CYP4F2 (0.86) CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2
SCHEMBL1859513 0.89 CYP4F2 (0.78) CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2
SCHEMBL8567928 0.87 CYP4F2 (0.63) CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2
SCHEMBL490584 0.87 IAPP (0.64) CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2
SCHEMBL16318789 0.87 CYP4F2 (0.62) CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2
SCHEMBL14360800 0.87 CYP4F2 (0.58) CYP4F2CYP4A11ALDH1A1NPC1PKM
SCHEMBL22098182 0.86 CYP4F2 (1.00) CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109134765-A A kind of polyisobutene and the graft copolymer of polyisoprene and preparation method thereof 北京化工大学 2019-01-04 — — CN claimed
CN-106366980-A Corrosion-resistant anaerobic adhesive 无锡万能胶粘剂有限公司 2017-02-01 — — CN claimed
WO-2013000595-A1 FLAVORING COMPOUND FIRMENICH SA (CH) 2013-01-03 — — WO claimed
US-20260078079-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES OSMO LABS PBC (US) 2026-03-19 — — US disclosed
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20260028554-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING AROMATIC DERIVATIVES OSMO LABS PBC (US) 2026-01-29 — — US disclosed
US-20250236810-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING BENZENE DERIVATIVES OSMO LABS, PBC 2025-07-24 — — US disclosed
US-20250234910-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING THIENYL ALKANOATE DERIVATIVES OSMO LABS, PBC 2025-07-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4519259-A1 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS Treeline Biosciences, Inc. (US) 2025-03-12 — — EP disclosed
WO-2025049827-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING PYRAZOLE DERIVATIVES OSMO LABS, PBC (US) 2025-03-06 — — WO disclosed
WO-1996036347-A1 USE OF LEUKOTRIENE ANTAGONISTS FOR ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1996-11-21 — — WO disclosed
EP-0743064-A1 Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease ELI LILLY AND COMPANY (US) 1996-11-20 — — EP disclosed
US-5462954-A Antiinflammatory, antiallergens; treating asthma ELI LILLY AND COMPANY (US) 1995-10-31 — — US disclosed
CN-1088906-A The phenyl phenol leukotriene antagonists that replaces LILLY CO ELI (US) 1994-07-06 — — CN disclosed
US-5235064-A Leukotriene antagonists ELI LILLY AND COMPANY (US) 1993-08-10 — — US disclosed
EP-0544488-A2 Substituted phenyl phenol leukotriene antagonists ELI LILLY AND COMPANY (US) 1993-06-02 — — EP disclosed
CN-1071423-A BICYCLIC CARBOXYLIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 1993-04-28 — — CN disclosed
US-5171882-A Leukotriene antagonists ELI LILLY AND COMPANY (US) 1992-12-15 — — US disclosed
US-4992576-A Antiinflammatory, antiallergens ELI LILLY AND COMPANY (US) 1991-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CYP4F2 170/4885CYP4A11 523/4885ALDH1A1 2667/4885
US-20250236810-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING BENZENE DERIVATIVES BBOX1, NISCH, TAS2R4 CYP4F2 476/4885CYP4A11 812/4885ALDH1A1 186/4885
US-20260028554-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING AROMATIC DERIVATIVES TAS2R42, TAS2R4, TAS2R41 CYP4F2 363/4885CYP4A11 698/4885ALDH1A1 868/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CYP4F2 192/4885CYP4A11 466/4885ALDH1A1 3142/4885
US-20260078079-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES CBR1, CBR3, TAS2R1 CYP4F2 915/4885CYP4A11 1615/4885ALDH1A1 804/4885
US-20250234910-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING THIENYL ALKANOATE DERIVATIVES TAS1R3, TAS2R5, TRPA1 CYP4F2 747/4885CYP4A11 951/4885ALDH1A1 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.